drugset / Trial / NCT04893512
First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects
NaSequentialOpen-labelPrevention
Summary
To evaluate the safety of 2 dose vaccination schedule of orally administered CoV2-OGEN1 In healthy subjects
Timeline
- Start
- 2021-06-30
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoV2-OGEN1 | Vaccine | 50 ug | Oral |
| Subject | CoV2-OGEN1 | Vaccine | 100 ug | Oral |
| Subject | CoV2-OGEN1 | Vaccine | 200 ug | Oral |